Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 453,162
  • Shares Outstanding, K 53,376
  • Annual Sales, $ 27,460 K
  • Annual Income, $ -46,050 K
  • EBIT $ -82 M
  • EBITDA $ -81 M
  • 60-Month Beta 1.97
  • Price/Sales 16.60
  • Price/Cash Flow N/A
  • Price/Book 6.44

Options Overview Details

View History
  • Implied Volatility 108.51% ( +29.86%)
  • Historical Volatility 40.61%
  • IV Percentile 65%
  • IV Rank 34.21%
  • IV High 258.40% on 07/30/24
  • IV Low 30.57% on 06/06/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 153
  • Volume Avg (30-Day) 393
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 15,618
  • Open Int (30-Day) 14,145

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.39
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.42
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +2.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.17 +3.92%
on 12/18/24
9.76 -13.01%
on 11/25/24
-0.48 (-5.35%)
since 11/20/24
3-Month
6.61 +28.44%
on 10/01/24
9.76 -13.01%
on 11/25/24
+0.43 (+5.33%)
since 09/20/24
52-Week
4.20 +102.14%
on 07/05/24
9.76 -13.01%
on 11/25/24
+3.74 (+78.93%)
since 12/20/23

Most Recent Stories

More News
Zevra Therapeutics, Inc. to be Added to Nasdaq Biotechnology Index Effective December 23, 2024

Zevra Therapeutics to join the Nasdaq Biotechnology Index effective December 23, enhancing its visibility in the biotech sector.Quiver AI SummaryZevra Therapeutics, Inc. announced that it will be added...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces Organizational Changes to Enhance Focus on Rare Disease Therapies

Zevra Therapeutics announces organizational changes to enhance focus on rare disease therapeutics, consolidating leadership and streamlining operations.Quiver AI SummaryZevra Therapeutics, Inc. has announced...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces Organizational Changes

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics CEO Neil F. McFarlane to Participate in December Investor Events

Zevra Therapeutics announces CEO Neil McFarlane's participation in December investor events focused on rare diseases.Quiver AI SummaryZevra Therapeutics, Inc., a company focused on treating rare diseases,...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics to Participate at Upcoming Investor Conferences

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces Availability of MIPLYFFAâ„¢, First FDA-Approved Treatment for Niemann-Pick Disease Type C, Through AmplifyAssistâ„¢ Patient Support Program

Zevra Therapeutics announces MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, now available via AmplifyAssist support program.Quiver AI SummaryZevra Therapeutics, Inc. announced...

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFAâ„¢ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics: Q3 Earnings Snapshot

ZVRA : 8.49 (-0.59%)
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

ZVRA : 8.49 (-0.59%)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 9.25
2nd Resistance Point 9.04
1st Resistance Point 8.77
Last Price 8.49
1st Support Level 8.28
2nd Support Level 8.07
3rd Support Level 7.79

See More

52-Week High 9.76
Last Price 8.49
Fibonacci 61.8% 7.64
Fibonacci 50% 6.98
Fibonacci 38.2% 6.32
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar